The US Food and Drug Administration (FDA) has published a warning letter addressed to the blood-pressure-tracking and wrist-wearable company Whoop, alleging it is marketing its new blood pressure feature without first getting proper approvals.
The FDA said Whoop’s Blood Pressure Insights (BPI) feature is intended to diagnose, cure, treat or prevent disease –